Join the 'Mycophenolic Acid' group to help and get support from people like you.
Mycophenolic Acid News
Posted 12 Nov 2015 by Drugs.com
THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more
Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Xolair, Imuran, Orencia, Chronic Kidney Disease, Revlimid, Leflunomide, Azathioprine, Arava, Afinitor, Tecfidera, Mycophenolate Mofetil, Peritoneal dialysis, Benlysta, Aubagio
Posted 23 Oct 2013 by Drugs.com
WEDNESDAY, Oct. 23 – Drugs meant to reduce the risk of organ rejection may increase the risk of miscarriage and birth defects when taken by female kidney transplant patients, according to a new study. The drugs – called mycophenolic acid products – reduce the risk of organ rejection by suppressing the immune system. The study included 163 female transplant patients who discontinued mycophenolic acid products prior to conception and 114 who conceived while taking the anti-rejection drugs. Those who stopped taking mycophenolic acid products before they became pregnant had more live births (79 percent vs. 43 percent), fewer miscarriages (19 percent vs. 52 percent) and a lower rate of birth defects (6 percent vs. 14 percent) than those who were taking the drugs when they conceived. Women who stopped the anti-rejection drugs before they became pregnant did not have an increased risk of ... Read more